On June 2, Intellia Therapeutics' (NTLA -0.96%) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement. This is a good omen Such patients might still technically have the disorder, as it is currently impossible for 100% of the copies of their genes, which are distributed across the my ...

Artur Plawgo Intellia Therapeutics (NASDAQ:NTLA) recently reported strong data from the Phase I portion of an ongoing Phase I/II study for NTLA-2002, an in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE). I have previously written about CRISPR Therapeutics (CRSP) and rated the company a strong buy due to its progress in the commercialization of Casgevy, an ex vivo CRISPR-based gene editing therapy. While CRISPR Therapeutics remains a strong buy, certain advantages of Intellia's therap ...

Intellia Therapeutics' (NTLA) shares gained 10% on Jun 3 after the company reported encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema (HAE). Shares of NTLA continued to gain another 1.1% in the after-market hours. Image Source: Zacks Investment Research A total of 10 patients are being treated in the phase I portion of the study with either of the three one-time doses (25 mg, 50 mg, or 75 mg) of NTLA-2002,administered ...

NTLA has rallied 10.9% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests NTLA could be on the verge of another move higher. Looking at NTLA's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 8 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. From a technical perspective, Intellia Therapeutics, Inc. (NTLA) is looking like an interestin ...

Intellia Therapeutics, Inc. (NTLA) reported first-quarter 2024 loss of $1.06 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.35. In the year-ago quarter, Intellia incurred a loss of $1.17 per share.The reported loss excluded a one-time expense of change in fair value of investments, net, including which the company reported a loss of $1.12 per share in the first quarter of 2024.The company’s total revenues currently comprise only collaboration revenues. NTLA reported revenues ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 (State or Other Jurisdiction ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President of Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Maury Raycroft - Jefferies Troy Langford - TD Cowen Luca Issi - RBC Capital Kosta ...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.48%. A quarter ago, it was expected that this company would post a loss of $1.47 per share when it actually produced a loss of $1.46, delivering a surprise of 0.68%.Over the last four quarters, the company h ...

Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May 9, 2024 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the first quarter ended March 31, 2024. "Intellia continues to make outstanding progress across our pipeline of in vivo and ex vivo single-do ...

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants sh ...